Zoetis IncZTS

Why is Zoetis (ZTS) moving?

Q3 202610 Jul – 29 Sep 2026

▲2▼2

Zoetis Q3: Pet Drug Woes, Fund Exit, Livestock Cushions

Major fund exits after 35% share plunge A large investment fund sold its Zoetis stake after the stock fell 35%, blaming competitive losses and poor execution. This high-profile exit signals deep investor concern and can pressure the share price further.
It shows a new negative force—major institutional selling—that emerged this quarter.
Dermatology loses 10 points of in-clinic share Zoetis's dermatology products lost 10 percentage points of market share in veterinary clinics, threatening its most profitable business. This intensifies competition from lower-priced rivals and could hurt future earnings.
It quantifies a new competitive loss in a key profit engine, a fresh negative development.
Livestock, diagnostics, international revenue grow Livestock revenue rose 11–12% (US up 23%), diagnostics grew 12%, and international revenue rose 8%. These areas provided a cushion against the weak pet-drug business, showing some resilience.
It highlights new positive offsets that partially counter the negative pet-drug trends.
Acquisition and pipeline progress Zoetis acquired VitalRADS and flagged over 12 potential blockbuster pipeline candidates. While these offer limited near-term profit, they mainly reduce downside risk and show investment in future growth.
It notes new strategic moves that could support long-term value, even if not immediate.

August 20263 Aug – 29 Sep 2026

▼2▲1

Zoetis cuts 2026 outlook as US pet sales slump

Guidance slashed on weak US pet demand Zoetis cut its 2026 revenue forecast to $9.12–$9.32 billion and EPS to $6.15–$6.25, after flat quarterly revenue and a 1% organic decline. US companion-animal sales fell 11% on fewer vet visits and price-sensitive pet owners. Lower expected profit pulls the stock down.
The guidance cut is the core new event that resets earnings expectations and drives the stock.
US dermatology share loss to rivals US dermatology in-clinic share dropped 10 percentage points from a year earlier as competition intensified. This is Zoetis's key legacy profit engine, so losing share there threatens the earnings base before newer pipeline products can make up the gap.
Share loss in the biggest franchise explains why growth stalled and why guidance fell.
Livestock and diagnostics offset weakness Livestock revenue rose 11–12%, with US livestock up 23%, and companion-animal diagnostics grew 12% to $118 million. International revenue rose 8% to $1.2 billion. These growing businesses cushion the pet-care decline and support future earnings.
These are the real counterweights keeping the decline from being worse and supporting the stock.
Pipeline and teleradiology deal offer future growth Zoetis flagged more than 12 potential blockbuster pipeline candidates and bought veterinary teleradiology platform VitalRADS. These could refill growth once legacy products slow, but they are years from contributing meaningfully, so they limit downside more than they lift near-term profit.
Shows the long-term offset management is betting on, balancing the negative guidance news.

Latest3 Aug – 29 Sep 2026

▼2▲1

Zoetis cuts 2026 outlook as US pet sales slump

Guidance slashed on weak US pet demand Zoetis cut its 2026 revenue forecast to $9.12–$9.32 billion and EPS to $6.15–$6.25, after flat quarterly revenue and a 1% organic decline. US companion-animal sales fell 11% on fewer vet visits and price-sensitive pet owners. Lower expected profit pulls the stock down.
The guidance cut is the core new event that resets earnings expectations and drives the stock.
US dermatology share loss to rivals US dermatology in-clinic share dropped 10 percentage points from a year earlier as competition intensified. This is Zoetis's key legacy profit engine, so losing share there threatens the earnings base before newer pipeline products can make up the gap.
Share loss in the biggest franchise explains why growth stalled and why guidance fell.
Livestock and diagnostics offset weakness Livestock revenue rose 11–12%, with US livestock up 23%, and companion-animal diagnostics grew 12% to $118 million. International revenue rose 8% to $1.2 billion. These growing businesses cushion the pet-care decline and support future earnings.
These are the real counterweights keeping the decline from being worse and supporting the stock.
Pipeline and teleradiology deal offer future growth Zoetis flagged more than 12 potential blockbuster pipeline candidates and bought veterinary teleradiology platform VitalRADS. These could refill growth once legacy products slow, but they are years from contributing meaningfully, so they limit downside more than they lift near-term profit.
Shows the long-term offset management is betting on, balancing the negative guidance news.

July 202610 Jul – 29 Jul 2026

▼3▲1

Zoetis hit by lawsuits, weak demand, and a major fund exit

Securities class action deadline looms Multiple law firms reminded investors of the July 27 deadline to seek lead plaintiff status in a securities fraud class action. The suit alleges Zoetis hid safety issues and market share losses, creating legal uncertainty and potential liability that weighs on the stock.
This is a new legal development that adds to the stock's negative overhang.
Weak Q1 results and guidance cut Zoetis reported Q1 revenue of $2.26 billion, up 2.9% but missing estimates, and cut full-year profit guidance. The CEO blamed price-sensitive pet owners and fewer vet visits, signaling softer demand for its pet medicines and pressuring the stock.
This is a new earnings report that directly impacts investor expectations for future growth.
Zoetis acquires VitalRADS Zoetis agreed to acquire VitalRADS, a Texas-based veterinary imaging services provider. This small deal could expand its service offerings and strengthen its veterinary diagnostics business, though the immediate financial impact is likely limited.
This is a new strategic move that could support long-term growth.
Major fund exits after 35% plunge Platinum International Brands Fund sold most of its Zoetis stake after shares fell 35% in the quarter, calling the investment a mistake. It cited rivals catching up in key products and disappointing commercial execution, adding to negative sentiment and selling pressure.
This is a new high-profile investor exit that reinforces concerns about competition and execution.

10 Jul – 29 Jul 2026

▼3▲1

Zoetis hit by lawsuits, weak demand, and a major fund exit

Securities class action deadline looms Multiple law firms reminded investors of the July 27 deadline to seek lead plaintiff status in a securities fraud class action. The suit alleges Zoetis hid safety issues and market share losses, creating legal uncertainty and potential liability that weighs on the stock.
This is a new legal development that adds to the stock's negative overhang.
Weak Q1 results and guidance cut Zoetis reported Q1 revenue of $2.26 billion, up 2.9% but missing estimates, and cut full-year profit guidance. The CEO blamed price-sensitive pet owners and fewer vet visits, signaling softer demand for its pet medicines and pressuring the stock.
This is a new earnings report that directly impacts investor expectations for future growth.
Zoetis acquires VitalRADS Zoetis agreed to acquire VitalRADS, a Texas-based veterinary imaging services provider. This small deal could expand its service offerings and strengthen its veterinary diagnostics business, though the immediate financial impact is likely limited.
This is a new strategic move that could support long-term growth.
Major fund exits after 35% plunge Platinum International Brands Fund sold most of its Zoetis stake after shares fell 35% in the quarter, calling the investment a mistake. It cited rivals catching up in key products and disappointing commercial execution, adding to negative sentiment and selling pressure.
This is a new high-profile investor exit that reinforces concerns about competition and execution.

Q2 202623 Jun – 3 Jul 2026

▼4

Zoetis hit by weak pet-drug sales, guidance cut, lawsuits, and index removal

Weak Q1 results and guidance cut Zoetis reported Q1 revenue of $2.26 billion, up 2.9% but missing estimates by 2.1%, and cut its 2026 revenue and EPS guidance. This signals slower growth and weaker demand for its pet medicines, pushing the stock down sharply.
Directly explains the earnings miss and lowered outlook that are driving the stock lower.
Companion animal sales slump and competition U.S. companion-animal sales fell 11%, with weaker demand for osteoarthritis treatments Librela and Solensia. Simparica Trio and dermatology products Apoquel and Cytopoint are losing market share to lower-priced rivals, hurting future revenue.
Identifies the core business weakness and competitive losses that are the root cause of the stock's decline.
Securities class action lawsuits Zoetis faces a securities fraud class action alleging it hid safety concerns and market share losses. Investors have until July 27, 2026 to seek lead plaintiff status. The lawsuit creates legal uncertainty and potential financial liability, weighing on the stock.
Legal risk is a major overhang that can affect investor confidence and future costs.
Removed from Russell Top 200 index Zoetis was removed from the Russell Top 200 and added to the Midcap Index, forcing index funds to sell the stock. This technical selling pressure adds to the stock's decline, though it doesn't change the underlying business.
Index reclassification triggers forced selling by funds, directly pressuring the share price.

June 202623 Jun – 3 Jul 2026

▼4

Zoetis hit by weak pet-drug sales, guidance cut, lawsuits, and index removal

Weak Q1 results and guidance cut Zoetis reported Q1 revenue of $2.26 billion, up 2.9% but missing estimates by 2.1%, and cut its 2026 revenue and EPS guidance. This signals slower growth and weaker demand for its pet medicines, pushing the stock down sharply.
Directly explains the earnings miss and lowered outlook that are driving the stock lower.
Companion animal sales slump and competition U.S. companion-animal sales fell 11%, with weaker demand for osteoarthritis treatments Librela and Solensia. Simparica Trio and dermatology products Apoquel and Cytopoint are losing market share to lower-priced rivals, hurting future revenue.
Identifies the core business weakness and competitive losses that are the root cause of the stock's decline.
Securities class action lawsuits Zoetis faces a securities fraud class action alleging it hid safety concerns and market share losses. Investors have until July 27, 2026 to seek lead plaintiff status. The lawsuit creates legal uncertainty and potential financial liability, weighing on the stock.
Legal risk is a major overhang that can affect investor confidence and future costs.
Removed from Russell Top 200 index Zoetis was removed from the Russell Top 200 and added to the Midcap Index, forcing index funds to sell the stock. This technical selling pressure adds to the stock's decline, though it doesn't change the underlying business.
Index reclassification triggers forced selling by funds, directly pressuring the share price.

23 Jun – 3 Jul 2026

▼4

Zoetis hit by weak pet-drug sales, guidance cut, lawsuits, and index removal

Weak Q1 results and guidance cut Zoetis reported Q1 revenue of $2.26 billion, up 2.9% but missing estimates by 2.1%, and cut its 2026 revenue and EPS guidance. This signals slower growth and weaker demand for its pet medicines, pushing the stock down sharply.
Directly explains the earnings miss and lowered outlook that are driving the stock lower.
Companion animal sales slump and competition U.S. companion-animal sales fell 11%, with weaker demand for osteoarthritis treatments Librela and Solensia. Simparica Trio and dermatology products Apoquel and Cytopoint are losing market share to lower-priced rivals, hurting future revenue.
Identifies the core business weakness and competitive losses that are the root cause of the stock's decline.
Securities class action lawsuits Zoetis faces a securities fraud class action alleging it hid safety concerns and market share losses. Investors have until July 27, 2026 to seek lead plaintiff status. The lawsuit creates legal uncertainty and potential financial liability, weighing on the stock.
Legal risk is a major overhang that can affect investor confidence and future costs.
Removed from Russell Top 200 index Zoetis was removed from the Russell Top 200 and added to the Midcap Index, forcing index funds to sell the stock. This technical selling pressure adds to the stock's decline, though it doesn't change the underlying business.
Index reclassification triggers forced selling by funds, directly pressuring the share price.